Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Advances In™ the Management of Chronic Immune Thrombocytopenia

Release Date: December 30, 2018
Expiration Date: December 30, 2019
Media: Internet - based

Activity Overview

This activity, Advances in™ the Management of Chronic Immune Thrombocytopenia, developed in Physicians’ Education Resource®, LLC established Advances in™ legacy format, will provide an overview of recent data on emerging options for the treatment of chronic immune thrombocytopenia (ITP), including FcRn inhibitors, spleen tyrosine kinase inhibition, and a novel thrombopoietin receptor agonist. You will hear expert discussion of long-term follow-up data for available therapeutic options. Topics will also include considerations for making treatment choices, including meeting the needs of the patient for optimizing therapeutic outcomes. You will benefit from expert opinion on how and when to incorporate new options into your treatment strategy for your patients. Benefits of Participating

By participating in this activity, you will learn about:

  • How expert opinion can inform therapy-sequencing choices in ITP treatment
  • Emerging data on novel agents and the biological rationale for new options in treating ITP
  • Considerations in long-term outcomes with systemic therapies for IT

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, pathologists, and nurses who treat patients with ITP. Nurse practitioners, physician assistants, pharmacists, and other healthcare professionals interested in the treatment of ITP are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the pathogenesis of chronic ITP and strategies to facilitate its early diagnosis
  • Differentiate between first and second-line treatment strategies for chronic ITP to optimize outcomes in adult patients
  • Examine potential treatment-associated adverse events and strategies to mitigate their impact on outcomes in the management of patients with ITP
  • Evaluate recent clinical trial evidence, including efficacy and safety profiles of current and novel therapeutic strategies for treatment of ITP

Faculty, Staff, and Planners' Disclosures


James B. Bussel, MD
Weill Cornell Medical College
NewYork-Presbyterian Hospital/
Weill Cornell Medical Center
New York, NY

Disclosures: Grant/ Research Support: Novartis, Amgen, Rigel, Protalex; Consultant: Momenta, UCB, Argenx, Dova, Amgen, Novartis, Rigel

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields

Become a Member

Forgot Password?
Calendar of Events
Filter By